Comment on this article
How Risky is Your Prostate Cancer?
July/August 2009
by Joshua Safran '93
Prostate cancer treatment has become
controversial—not because the disease is usually deadly, but because it so
often isn’t. Many men have microscopic, slow-growing malignancies in the prostate
gland that would not cause health problems and would never have been diagnosed
if not for the sensitive blood test now standard. Yet because clinicians have
had limited ability to determine which cases of prostate cancer are genuinely
life threatening, patients may unnecessarily receive aggressive treatment that
can cause incontinence or impotence.
|
Aggressive treatment can cause incontinence or impotence.
|
New research by John Concato, professor of medicine,
and his colleagues may point the way toward a solution. Concato’s team examined
initial biopsy tissue from 1,007 men diagnosed with prostate cancer between
1991 and 1995, and then tracked these patients' health status through 2006.
In the May 5 Annals of Internal Medicine, they identified three biomarkers
correlated with greater mortality—two gene variants and high microvessel
density. "Based on our findings, more than a third of men would be at higher
risk according to the status of their markers," Concato said.
An accompanying editorial criticized the study for
the relatively small number of biomarkers it tested and limited likely effect
on clinical practice. Concato acknowledged that the work might not change
initial treatment patterns, but said the markers could help distinguish
patients who would likely need more-intensive treatment later, and that new,
targeted therapies might be developed based on the markers.
And biomarker testing may also help inform patients
and their families, he said. "If a relative of mine was diagnosed with prostate
cancer, I would want to know their marker status.”  |
